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Abstract
Background: Depression in patients with brain tumors is associated with impaired quality of life and shorter
survival. Altered metabolism of tryptophan to serotonin and kynurenine metabolites may play a role in tumor-
associated depression. Our recent studies with alpha[11C]methyl-L-tryptophan (AMT)-PET in brain tumor patients
indicated abnormal tryptophan metabolism not only in the tumor mass but also in normal-appearing contralateral
brain. In the present study, we explored if tryptophan metabolism in such brain regions is associated with
depression.
Methods: Twenty-one patients (mean age: 57 years) with a brain tumor (10 meningiomas, 8 gliomas, and 3 brain
metastases) underwent AMT-PET scanning. MRI and AMT-PET images were co-registered, and AMT kinetic
parameters, including volume of distribution (VD’, an estimate of net tryptophan transport) and K (unidirectional
uptake, related to tryptophan metabolism), were measured in the tumor mass and in unaffected cortical and
subcortical regions contralateral to the tumor. Depression scores (based on the Beck Depression Inventory-II [BDI-II])
were correlated with tumor size, grade, type, and AMT-PET variables.
Results: The mean BDI-II score was 12 ± 10 (range: 2–33); clinical levels of depression were identified in seven
patients (33 %). High BDI-II scores were most strongly associated with high thalamic AMT K values both in the
whole group (Spearman’s rho = 0.63, p = 0.004) and in the subgroup of 18 primary brain tumors (r = 0.68, p = 0.004).
Frontal and striatal VD’ values were higher in the depressed subgroup than in non-depressed patients (p < 0.05); the
group difference was even more robust when moderately/severely depressed patients were compared to patients
with no/mild depression (frontal: p = 0.005; striatal: p < 0.001). Tumor size, grade, and tumor type were not related
to depression scores.
Conclusions: Abnormalities of tryptophan transport and metabolism in the thalamus, striatum, and frontal cortex,
measured by PET, are associated with depression in patients with brain tumor. These changes may indicate an
imbalance between the serotonin and kynurenine pathways and serve as a molecular imaging marker of brain
tumor-associated depression.
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Background
Brain tumors comprise of about 90 % of all primary central
nervous system tumors. In adults, meningiomas are the
most common benign primary brain tumors, accounting
for approximately 30 % of all brain tumors [1], while
gliomas and metastatic brain tumors are the most fre-
quently diagnosed malignancies in the brain parenchyma.
Glioblastomas, the most malignant histologic type, com-
prise 65 % of all gliomas [2]. While brain tumors commonly
manifest with seizures and focal neurological symptoms,
cognitive impairment, mood disturbance, and depression
are also common co-morbidities [3, 4]. In the general popu-
lation, the prevalence estimates of major depressive dis-
order (MDD) were 14.9 % over a lifetime and 8.6 % over
12 months in the National Comorbidity Survey [5].
Most epidemiologic data related to brain-tumor-
associated depression have encompassed primarily glioma
patients, where the estimated prevalence of depression
ranges from 6 to 93 % [3]. In a large study (n = 155), 20 %
of newly diagnosed glioma patients fulfilled the diagnostic
criteria of MDD. According to a systematic review,
depression occurred independently of most tumor- or
treatment-related variables, including brain tumor type,
histologic grade, location, or various treatment modalities
[6]. While depression in brain tumor patients is an
important component of the quality of life, and, possibly,
survival [6–8], many patients are neither properly diag-
nosed nor adequately treated for depression. Effective
treatments for MDD include antidepressants (such as
serotonin reuptake inhibitors) and psychotherapy. In a
retrospective study of 160 glioblastoma patients, serotonin
reuptake inhibitor treatment appeared to have some bene-
ficial effect on survival after controlling for age and other
prognostic factors [9]. In another study, presence of pre-
operative depression predicted worse survival in patients
with low-grade gliomas [7]. In addition, preclinical studies
suggested a direct chemotherapeutic effect of antidepres-
sants in gliomas: both selective serotonin reuptake inhibi-
tors (SSRIs) and tricyclic antidepressants induced glioma
cell death by apoptosis in cell cultures [10, 11].
The precise pathophysiology of cancer-associated depres-
sion remains to be further elucidated. One theory involves
an abnormal psychological reaction to overwhelming stress
and loss [8, 12]. Another long-standing biological theory is
related to abnormal serotonin levels due to a systemic shift
between serotonin to kynurenine metabolism of tryptophan
commonly referred to as the “kynurenine shunt” [13]. This
effect has been described mostly in the context of major
depression, where immune-mediated activation of indolea-
mine 2,3-dioxygenase (IDO), the initial key enzyme of the
kynurenine pathway, and related decrease in serotonin syn-
thesis have been considered key elements of the patho-
physiology [14–16]. Increased pro-inflammatory cytokine
levels have been linked to cancer-associated depression,
partly via IDO activation, which may also lead to changes
in brain serotonin levels [17–19]. Whether this mechanism
plays a role in brain tumor-associated depression depres-
sion requires further study.
Molecular imaging of brain tryptophan metabolism and
serotonergic function is a relatively new approach to study
cerebral substrates of mood disorders and depression.
Alpha[11C]methyl-L-tryptophan (AMT) is a positron
emission tomography (PET) radiotracer accumulated in
serotonergic neurons and is also a substrate of IDO of the
kynurenine pathway [20–22]. AMT-PET studies in
patients with MDD suggested focal abnormalities of brain
serotonin synthesis [23–26]. Application of AMT-PET has
also been studied in brain tumor imaging: AMT is accu-
mulated in various brain tumors, and kinetic AMT-PET
parameters are able to differentiate various brain tumor
types, assess glioma proliferative activity, and estimate
IDO and tryptophan 2,3-dioxygenase expression in both
gliomas and meningiomas [27–32]. Interestingly, our
recent studies in patients with brain tumors who under-
went AMT-PET scan also demonstrated abnormal AMT
uptake and kinetics in non-tumoral brain regions contra-
lateral to the tumor [33, 34]. In patients with post-
treatment malignant gliomas, altered AMT uptake in the
contralateral cortex and thalamus was observed, and high
thalamic uptake was a predictor of shorter survival [34].
In the present study, we used AMT-PET to explore the
potential role of abnormal tryptophan metabolism in brain
tumor-associated depression depression. We hypothesized
that higher depression scores assessed at the time of the
PET scan would be associated with abnormalities of AMT
kinetic variables in the non-tumoral hemisphere. We also
assessed if such changes were related to tumor type, histo-
logic grade, or previous treatment. The overall goal of these
studies was to determine if abnormal brain tryptophan me-
tabolism, measured by PET, could be an imaging biomarker
for brain tumor-associated depression.
Methods
Patient population
The study population included 21 patients (mean age:
57 years) with a brain tumor. Histopathology showed 10
World Health Organization (WHO) grade 1 meningi-
omas, 8 WHO grade 1–4 gliomas, and 3 brain metastases
(1 breast cancer, 1 melanoma, and 1 non-small cell lung
cancer) (Table 1). The four post-treatment patients had
previous resective surgery with or without subsequent
chemoradiation. Serial magnetic resonance imaging (MRI)
follow-up demonstrated tumor progression or recurrence
in all four patients; one patient also showed clinical pro-
gression. None of the 21 patients had a history of clinical
depression, and they were not on any antidepressants at
the time of the PET scan. All patients had a Karnofsky
Performance Status score of 70 or higher. All patients
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were screened for depression on the day of the AMT-PET
scan (see details below). Six of the 21 patients were on
dexamethasone (which did not affect AMT kinetic values
in non-tumoral brain in our previous study [33]), 10 pa-
tients had a history of seizure(s), and 12 were on antiepi-
leptic medication at the time of the AMT-PET scan. The
study was approved by the Institutional Review Board of
Wayne State University (#091602MP2F(5R)), and written
informed consent was obtained from all participants.
AMT-PET scanning protocol
Fifteen of the 21 AMT-PET studies were performed
using a GE Discovery STE PET/CT scanner (GE Medical
Systems, Milwaukee, WI) and six scans were performed
using a Siemens EXACT/HR whole-body positron emis-
sion tomograph, both located at the PET Center of the
Children’s Hospital of Michigan in Detroit. Both scan-
ners have a 15-cm field of view and generate 47 image
planes with a slice thickness of 3 mm. The reconstructed
image in-plane resolution obtained is 7.5 ± 0.4 mm at
full-width half-maximum (FWHM) and 7.0 ± 0.5 mm in
the axial direction (reconstruction parameters: Hanning
filter with 1.26 cycles/cm cutoff frequency) for the Sie-
mens scanner. The GE scanner has a similar resolution,
with FWHM of 7.5 mm (isotropic), and images from this
scanner were reconstructed with an iterative reconstruc-
tion (2 iterations, 16 subsets, 8-mm axial smoothing).
The AMT tracer was synthesized using a high-yield pro-
cedure as previously outlined [35]. The procedure for
AMT-PET scanning has been described in detail else-
where [27]. In short, following 6 h of fasting, a slow
bolus of AMT (3.7 MBq/kg) was injected intravenously
over 2 min. For collection of timed blood samples, a
second intravenous line was established. In the initial
20 min of the scan following tracer injection, a dynamic
PET scan of the heart was performed to obtain the blood
input function from the left cardiac ventricle non-
invasively. The blood input function was continued
beyond these initial 20 min by using venous blood sam-
ples (0.5 mL/sample, collected at 20, 30, 40, 50, and
60 min after AMT injection). At 25 min after tracer in-
jection, a dynamic emission scan of the brain (7 × 5 min)
was obtained. Measured attenuation correction, scatter,
and decay correction were applied to all PET images.
MRI protocol
Diagnostic MRI scans with routine post-gadolinium T1
(T1-Gad), T2-weighted, and fluid-attenuated inversion
Table 1 Clinical data, BDI-II depression scores, imaging and histopathology data of the patients, who are listed in the order of
decreasing BDI-II scores
Gender Age (years) BDI-II score New/rec Tumor type Grade Area max (cm2) Location Side
1 F 55 33 New Glioma 4 12.9 FP R
2 F 22 30 New Meningioma 2 8.5 F R
3 M 52 28 New Meningioma 1 12.2 Brainstem M
4 M 67 22 New Metastasis 1.8 F R
5 M 70 20 New Metastasis 17.7 TP L
6 M 63 17 Rec Glioma 2 43.6 FT R
7 M 48 14 New Glioma 3 25.3 F L
8 F 49 13 New Meningioma 1 9.6 F L
9 M 59 11 New Meningioma 1 4.6 Medulla M
10 F 37 9 New Glioma 2 11.8 F L
11 M 58 8 Rec Meningioma 2 8.7 P R
12 M 25 6 New Glioma 1 1 O R
13 M 46 6 Rec Glioma 4 2.6 PO, T R
14 F 60 6 New Metastasis 1.1 F L
15 F 84 5 New Meningioma 1 13.8 F L
16 F 70 5 New Glioma 4 1.6 T R
17 M 60 3 New Meningioma 1 13.2 Olfactory M
18 F 62 3 New Meningioma 6.2 FT L
19 M 68 3 New Meningioma 5.1 R lat clivus R
20 M 79 2 New Glioma 4 6.1 T L
21 M 68 2 New Meningioma 1 9.1 F L
BDI-II Beck Depression Inventory-II, M male, F female, new/rec newly diagnosed/recurrent tumor, F frontal, T temporal, P parietal, O occipital, R right, L left, M
midline, lat lateral
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recovery (FLAIR) axial images acquired closest in time
(typically within 2 weeks) to the AMT-PET were used in
the study. MRI was performed on one of three 3T scan-
ners using similar parameters: (i) Siemens MAGNETOM
Trio TIM, (ii) GE Signa HDxt, or (iii) Philips Achieva
TX.
AMT-PET image processing and analysis
For visualization of AMT uptake in the brain, averaged ac-
tivity images 30–55 min post-injection were created and
converted to an AMT standardized uptake value (SUV)
image. For quantification of AMT accumulation, a Patlak
graphical analysis was performed using the dynamic brain
PET images and blood input function [27, 36]. This
approach provides two main kinetic parameters. The y-
intercept of the Patlak plot yields the tracer’s apparent
volume of distribution (VD’), which is tightly correlated
with VD values derived from compartmental analysis
[21, 27, 37]; AMT VD’ values are indicative of the net
transport of tryptophan into the tissue of interest
(tumor or cortex). The slope of the Patlak plot (K-com-
plex or K) reflects the unidirectional uptake of the
tracer into the tissue and correlates with tryptophan
metabolism via the serotonin synthesis pathway in
cortex [21, 22]. In brain tumors, with no evidence of
serotonin synthesis, the most likely mechanism of an
increase in AMT K-complex is tumoral accumulation
in the form of either unmetabolized AMT or kynure-
nine metabolites. The advantages and limitations of
using these kinetic AMT-PET parameters have been
discussed previously [21, 27, 30]. For image analysis,
the 3D Slicer 3.6.3 software suite was used (Brigham
and Women’s Hospital, Inc.) as described previously
[32, 34, 38, 39]. First, a transformation matrix was created
by co-registration of the summed AMT-PET images to
the T1-Gad volumetric image volumes (magnetization-
prepared rapid gradient-echo [MPRAGE] protocol on
Siemens or MPRAGE-equivalent sequence on GE and
Philips scanners) as well as FLAIR images using the Fast
Rigid Registration module. This transformation matrix
was then applied to the summed AMT-PET image and to
the dynamic AMT-PET images loaded via the 4D Image
module of the 3D Slicer. Following fusion of the summed
AMT-PET with MR images, the largest orthogonal diame-
ters as well as maximum tumor area on T1-Gad (or T2/
FLAIR images, if no enhancement was seen) were mea-
sured. Regions of interest (ROIs) were drawn on the
tumor mass in tumor regions with contrast enhancement
and/or T2/FLAIR signal changes on MRI. In addition, cor-
tical and subcortical regions, contralateral to the tumor,
were delineated and analyzed as described recently [34];
for the three tumors close to the midline, the tumor side
was defined as the side with the larger tumor mass. In
brief, regions of interest were segmented manually using
the axial view of the PET/MRI fusion images (Fig. 1). The
ROIs included gray matter voxels with AMT uptake: a
single plane for the thalamus and striatum with the largest
axial diameter and multiple planes (one to two planes
apart) for the cortical ROIs including the frontal (three
planes), temporal (two planes), and parietal (two planes)
lobes. None of these ROIs showed abnormal contrast-
enhancement or FLAIR signal on co-registered MR
images. Similar to our previous study, the occipital cortex,
which often shows high physiologic AMT uptake, was not
included in the analyses. All tumoral and contralateral
cortical and subcortical ROIs were applied on the co-
registered AMT SUV as well as dynamic PET images, and
AMT SUV as well as K and VD’ values from the Patlak
analysis was obtained for each region.
Assessment of depression
Symptoms of depression were assessed using the Beck De-
pression Inventory, 2nd Edition (BDI-II) [40]. The BDI-II
is a self-reported measure that identifies the presence and
severity of symptoms of depression. There are 21 items on
the BDI-II each rated on a four-point Likert scale (0–3).
The measure yields a total score, and the cutoffs for de-
pression severity are as follows: 0–13 = no/minimal
depression, 14–19 =mild depression, 20–28 =moderate
depression, and 29–63 = severe depression. The
Fig. 1 AMT-PET/T1-Gad MRI fusion images of a patient (#10) with left frontal WHO grade 2 glioma. Contralateral frontal, parietal, and temporal
cortical, as well as thalamic and striatal regions of interest used for analysis, are outlined in red
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psychometric properties of the scale have been well
established, and the measure is widely used with both
clinical and research samples including different cancer
patient groups [6–8, 41, 42].
Statistical analysis
First, BDI-II depression scores were compared among
three tumor types (gliomas, meningiomas, metastases)
using the Kruskal-Wallis test. BDI-II depression scores
were also correlated with tumor type, histologic grade,
tumor size, and AMT-PET variables in the whole group
as well as subgroups (such as patients with a primary
brain tumor, patients with an intraaxial tumor [glioma
or metastasis], and patients with a newly diagnosed
tumor) using Spearman’s rank correlations. AMT
kinetic variables were compared between depressed
(BDI-II score >13) and non-depressed patients, as
well as between moderately/severely depressed pa-
tients (BDI-II score ≥20) vs. the rest of the patients,
using the Mann-Whitney U test. Statistical analyses
were performed using IBM SPSS Statistics, version




Mean BDI-II total score was 12 ± 10 (range: 2–33). A
total of seven patients (33 %) had scores indicating vari-
ous levels of depression: five patients (24 %) had moder-
ate or severe depression (BDI-II score ≥20), and two
additional patients had mild depression (Table 1). Mean
BDI-II scores (gliomas: 12 ± 10, meningiomas: 11 ± 10,
metastases: 16 ± 9) were not different across tumor
types, p = 0.47.
In the whole group, the BDI-II depression scores
showed a significant positive correlation with thalamic
and temporal cortical K values, with the most robust
correlations found for the thalamic values (r = 0.63; p =
0.004), that remained significant even after Bonferroni
correction for multiple correlations (Additional file 1:
Table S1, Fig. 2). In comparison of depressed (n = 7) vs.
not depressed patients, frontal and striatal VD’ values
were significantly higher in the depressed subgroup
(0.40 ± 0.10 vs. 0.31 ± 0.06, p = 0.017 and 0.53 ± 0.19 vs.
0.36 ± 0.07, p = 0.035, respectively). The difference was
even more robust when moderately/severely depressed
patients (n = 5) were compared to patients with no/mild
depression (frontal VD’: 0.43 ± 0.10 vs. 0.31 ± 0.06, p =
0.005; striatal VD’: 0.61 ± 0.16 vs. 0.35 ± 0.07, p < 0.001)
(Fig. 3). Tumor size, tumor grade (in the primary brain
tumors), tumor type, tumoral AMT-PET variables, and
AMT SUVs in any structures were not related to the
depression scores.
Subgroup analysis
In the 18 patients with primary tumors (gliomas and men-
ingiomas), thalamic as well as temporal and parietal cor-
tical K values showed significant positive correlations with
BDI-II depression scores (Additional file 1: Table S2); the
most robust correlation was again found with thalamic K
values (r = 0.68; p = 0.004), similar to the whole-group re-
sults. In the 12 patients with an intraaxial tumor, only
thalamic K values showed a positive correlation with the
BDI-II depression scores (r = 0.65, p = 0.03). Finally, in the
pretreatment subgroup (n = 18), thalamic AMT K values
showed a positive correlation with the BDI-II depression
scores (r = 0.61; p = 0.013).
Fig. 2 Positive correlation between thalamus AMT K values and BDI-
II depression scores (Spearman’s rho = 0.63, p = 0.004)
Fig. 3 Comparison of AMT-PET variables in patients with no/mild
depression vs. moderate/severe depression. Frontal and striatal AMT
volume of distribution (VD’) values were significantly higher in
patients with moderate/severe depression (frontal VD’: 0.43 vs. 0.31,
p = 0.005; striatal VD’: 0.61 vs. 0.35, p < 0.001)
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Discussion
Although there have been past studies showing focal brain
abnormalities of tryptophan metabolism in patients with
depression not associated with cancer [24–26], this is the
first study to assess imaging correlates of cerebral trypto-
phan metabolism in brain tumor-associated depression
depression. Similar to previous studies, we noted a high
rate of depression (one third in our cohort) in a group of
patients with a brain tumor, who were not previously diag-
nosed and treated for depression clinically. Our main find-
ing is that higher depression scores were related to
variations in tryptophan kinetic variables in several cortical
and subcortical structures contralateral to the tumors in
brain regions showing no apparent MRI abnormalities. Spe-
cifically, depressed patients showed higher AMT VD values
(suggesting higher tryptophan transport) in the frontal cor-
tex and striatum, two key components of the fronto-striatal
network, previously implicated in depressive symptoms
[43]. These increases are likely related to the upregulation
of the kynurenine pathway, thus leading to an imbalance
between tryptophan metabolism via the serotonin and
kynurenine pathways. Such an imbalance may play a role in
brain tumor-associated depression depression.
In previous AMT-PET studies in patient groups with
depression not associated with cancer, decreased trypto-
phan metabolism was found in the anterior cingulate
cortex as well as the mesial temporal cortex in MDD
patients [23] and in the frontal cortex (orbital and
ventromedial prefrontal regions) in suicide attempters
[24]. Another study reported increased tryptophan me-
tabolism in the prefrontal cortex after combined anti-
depressant treatment (SSRI plus 5-HT1A receptor
antagonist pindolol) in MDD patients [26]. Frey et al.
[25] also reported regional gender differences in MDD,
with higher focal tryptophan metabolism in multiple
brain regions, such as the anterior cingulate cortex, in-
ferior frontal gyrus, parahippocampal gyrus, precuneus,
superior parietal lobule, and occipital lingual gyrus, in
women. However, previous imaging studies of cerebral
structural or functional correlates of cancer-associated de-
pression are limited. 2-deoxy-2[18F]fluoro-D-glucose
(FDG)-PET studies showed decreased glucose metabolism
in limbic structures, such as the anterior and posterior
cingulate gyri, basolateral frontal cortices, dorsolateral
prefrontal cortex (DLPFC), temporo-parietal cortices, in-
sular cortex, and also in the basal ganglia in depressed
patients with different types of cancer (malignant melan-
oma, malignant lymphoma, cervical cancer, pancreatic
cancer, and colon cancer) [44, 45]. A subsequent FDG-
PET study, in a heterogeneous extracranial cancer popula-
tion with predisposition to onset of depression, showed
decreased glucose metabolism in the right medial frontal
gyrus but increased metabolism in the right anterior and
posterior cingulate gyri, left subcallosal gyrus, and left
caudate nucleus [46]. Increased metabolism in the sub-
genual anterior cingulate cortex was also reported in pan-
creatic cancer patients with minor and major depression
[47]. One study investigating FDG uptake changes during
an attention task in breast cancer patients found de-
creased glucose metabolism in the bilateral DLPFC and
right premotor cortex, as well as in the left inferior par-
ietal lobe in depressed patients [48]. Altogether, these
glucose PET findings showed metabolic abnormalities in
some of the brain structures found to show depression-
related variations in our present study, including fronto-
temporal cortices and the basal ganglia. Also consistent
with this, FDG-PET studies performed in patients with
MDD (not associated with cancer) showed decreased
brain metabolism in similar brain regions, including the
prefrontal cortex, basal ganglia, and temporo-parietal cor-
tices [49, 50]. In addition, increased glucose metabolism
in the orbital cortex, amygdala, and thalamus was re-
ported in some studies [51, 52]. Overall, these data
strongly suggest that the main neural substrates of de-
pression are similar in cancer patients and those with
major depression.
The abovementioned structures, showing metabolic
changes in depressed patients, are parts of specific brain
circuits that play a role in depressive symptoms, such as
the fronto-striatal and limbic circuits. A functional MRI
(fMRI) study reported a possible role of fronto-striatal
circuits in MDD [43] by showing attenuated functional
connectivity between the ventral striatum and both
ventromedial prefrontal cortex and subgenual anterior
cingulate cortex and also stronger connectivity between
dorsal caudate and dorsal prefrontal cortex, which corre-
lated with the severity of depression. Another fMRI
study showed increased network functional connectivity
in the subgenual cingulate, thalamus, and orbitofrontal
cortex in depressed patients [53]. Interestingly, a histo-
pathology study from postmortem issues demonstrated
elevated total neuron number in the limbic thalamus re-
gion in MDD patients [54]. Also, a postmortem study in
suicide patients with MDD demonstrated increased
microglia density in the DLPFC, anterior cingulate cor-
tex, and mediodorsal thalamus [55]. This latter finding
suggested active immunological processes and neuroin-
flammation in some of the brain regions whose trypto-
phan kinetic parameters showed a correlation with
depression scores in our study.
One concern with the use of the BDI-II in subjects with a
somatic disease is that the total score may, at least partially,
reflect the disease severity rather than clinical depression.
For example, a previous study demonstrated that the som-
atic subscale score may be better attributed to the severity
of the cancer disease, rather than the severity of depression
[56]. In a recent study of brain tumor patients, the somatic
subscale score provided the strongest contribution to the
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total variance of the Beck score [57]. Another study showed
that elderly patients with co-morbidities have higher scores
on the somatic subscale than younger subjects [58]. In our
study, an exploratory analysis showed that the somatic
subscale scores had the strongest correlation with thalamic
AMT uptake, while the cognitive-affective scores also
correlated with fronto-striatal tryptophan kinetic variables
(data not shown). Although this observation will need to be
addressed in a larger study, it is possible that tryptophan
metabolic changes in the thalamus are more related to the
cancer-associated somatic symptoms, while the fronto-
striatal tryptophan changes are more tightly associated with
clinical depression. This latter is further supported by the
finding that depressed brain tumor patients showed higher
AMT VD values in the frontal cortex and striatum without
significant differences in the thalamus.
The exact cause of higher tryptophan kinetic parame-
ters measured in non-tumoral brain regions of depressed
brain tumor patients remains to be determined. A plaus-
ible mechanism would be higher tryptophan demand
due to increased tryptophan metabolism via the kynure-
nine pathway. IDO, the rate-limiting enzyme of this
pathway, is upregulated by pro-inflammatory cytokines,
which are known to increase as a result of chronic
inflammatory responses in various inflammatory disor-
ders and cancer; a main source of cytokine release in the
brain is derived from activated microglia, and this mech-
anism is implicated in the pathophysiology of cancer-
associated depression [19, 59–61]. In addition, tumor
treatment effects, especially radiation, may also induce
brain inflammatory responses [62]. This is unlikely to be
the main mechanism in our study, because the majority
of the patients had no previous treatment, and the key
findings remained significant in the pretreatment sub-
group. A third possibility for increased tryptophan kinet-
ics in remote brain regions could be the presence of
microscopic tumor infiltration, not visualized on MRI.
This could occur in some infiltrative gliomas or brain
metastases, but not in patients with meningiomas; there-
fore, this is also an unlikely explanation. The observed
variations in tryptophan kinetics may be also modulated
by simultaneous changes in serotonin synthesis (often
seen as decreased in depression). This makes the inter-
pretation of our PET findings more complicated, since
AMT can track both the kynurenine and serotonin
pathways [22]. Additional imaging studies, employing
radioligands specific for the kynurenine or serotonin
pathways, could clarify this issue. Such ligands, such as
radiotracers tracking IDO activity, are being currently
developed [63, 64]. The role of neuroinflammation in
brain tumor-associated depression depression could
also be further studied by molecular imaging ap-
proaches targeting activated microglia, e.g., by using
PET radioligands for the translocator protein [65].
This study has some limitations. The study population
was small; therefore, potential tumor-type-specific ef-
fects could not be completely excluded (although major
effects were not detected). Also, our analysis was con-
fined to a limited number of brain regions and did not
include some potentially relevant structures, such as the
amygdala. However, spatial resolution of AMT-PET is
limited, which makes reliable assessment of detailed
tracer kinetics in small regions difficult. Another poten-
tial confounding factor could be the effect of brain
volume loss on PET metabolic values. Volumetric MRI
studies indeed demonstrated variable volume decreases
in a number of cortical and subcortical brain regions in
depressed patient populations [66–70], although the
results were inconsistent. In a recent study of MDD pa-
tients, reduced striatal volume was inversely associated
with serum kynurenine and kynurenine/tryptophan ra-
tios [71]. Although brain volumetric data on cancer-
associated depression are scarce, the higher tryptophan
kinetic parameters in depressed patients in our study
cannot be explained by volume loss, which would likely
result in lower (rather than increased) tracer uptake in
these structures. Finally, we did not have AMT kinetic
data in an age-matched healthy control group to assess
if the observed, depression-related variations of AMT-
PET parameters in the studied regions were outside of
the physiologic range. Thus, these study results will need
to be further confirmed in a larger patient population
and compared to data of healthy control subjects.
Conclusions
These results demonstrate that tryptophan transport and
metabolism in the thalamus, striatum, and fronto-temporal
cortex are associated with depression in patients with a
brain tumor. The observed imaging abnormalities may in-
dicate an imbalance between the serotonin and kynurenine
pathways. Altered tryptophan metabolism in non-tumoral
brain, measured by PET, may be a novel imaging marker of
brain tumor-associated depression.
Additional file
Additional file 1: BDI-II scores and AMT kinetic parameters. Table S1.
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